CHC – The Cancer & Hematology Centers

AT148002 (ALX Oncology)

AT148002 (ALX Oncology)

 Description:   A Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS)

Mechanism of Action:  ALX148 is a CD47 blocker.

Target Patient Population: High Risk MDS

Study Design:  Study Drug will be administered IV every 2 or 4 weeks.  Combination drug, Azacitidine given as would Standard of Care.